Literature DB >> 3494816

Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide.

H Minagawa, A Takenaka, Y Itoyama, R Mori.   

Abstract

Relapse of experimental allergic encephalomyelitis (EAE) was achieved in Lewis rats by cyclophosphamide (CY). All rats, immunized with an emulsion of guinea pig spinal cord homogenate in complete Freund's adjuvant and treated with 100 mg/kg of CY 21 days postimmunization (pi), developed moderate to severe paralysis 9-14 days following CY injection. A second relapse was observed in 4 of 11 rats reinjected with CY 49 days pi. Histologically, focal mononuclear cell infiltration with or without demyelination of the white matter of the central nervous system was observed. Cyclophosphamide administration caused transient leukopenia and T-cell defect, the resolution of which coincided with relapse of clinical EAE. Lymphocyte proliferative responses to myelin basic protein (BP) and concanavalin A (Con A) and antibody titers to BP were preserved in CY-treated rats. Adoptive transfer of EAE to naive recipients with Con A-activated spleen cells from donors with CY-induced relapse was unsuccessful.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494816     DOI: 10.1016/0022-510x(87)90063-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

1.  Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice.

Authors:  A P Kuruvilla; R Shah; G M Hochwald; H D Liggitt; M A Palladino; G J Thorbecke
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

2.  The role of serum factors in the suppression of experimental allergic encephalomyelitis: evidence for immunoregulation by antibody to the encephalitogenic peptide.

Authors:  I A MacPhee; M J Day; D W Mason
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

3.  The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.

Authors:  Ester Reggio; Alessandra Nicoletti; Teresa Fiorilla; Guido Politi; Arturo Reggio; Francesco Patti
Journal:  J Neurol       Date:  2005-06-06       Impact factor: 4.849

4.  Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.

Authors:  Francesco Patti; Ester Reggio; Filippo Palermo; Teresa Fiorilla; Guido Politi; Alessandra Nicoletti; Arturo Reggio
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

5.  Regulation of resistance against adjuvant arthritis in the Fisher rat.

Authors:  A G van de Langerijt; P L van Lent; A R Hermus; L B van de Putte; W B van den Berg
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

6.  Necrotizing chorioretinitis in mice inoculated with herpes simplex virus type 1 with or without glycoprotein C: anterior chamber-associated immune deviation does not persist.

Authors:  Y Liu; H Minagawa; Y Toh; Y Sakai; T Ishibashi; H Inomata; R Mori
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

7.  Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis.

Authors:  K Mangano; A Nicoletti; F Patti; M Donia; L Malaguarnera; S Signorelli; G Magro; V Muzio; B Greco; P Zaratin; P Meroni; M Zappia; F Nicoletti
Journal:  Clin Exp Immunol       Date:  2009-11-18       Impact factor: 4.330

Review 8.  Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.

Authors:  Dimitrios Karussis; Panayiota Petrou
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

9.  Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids.

Authors:  I A MacPhee; F A Antoni; D W Mason
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.